FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2001503306> ?p ?o ?g. }

• W2001503306 endingPage "1340" @default.
• W2001503306 startingPage "1340" @default.
• W2001503306 abstract "Recombinant feline interferon-omega (rFeIFN-omega) was tested as a treatment option for cats with fibrosarcoma to assess safety and feasibility.Treatment with rFeIFN-omega in cats with fibrosarcoma is safe and feasible.Twenty domestic cats.In an open-labeled uncontrolled clinical trial 12 injections of 1 x 10(6) U/kg rFeIFN-omega were administered over a 5-week period: the 1st through 4th injections were given intratumorally, and the 5th through 12th injections were administered subcutaneously at the tumor excision site. Wide surgical excision of the tumors was carried out after the 4th injection and before the 5th injection of rFeIFN-omega. A Common Terminology Criteria for Adverse Events (CTCAE) analysis was conducted. Flow cytometry of fibrosarcoma cells after incubation with rFeIFN-omega and recombinant feline interferon-gamma was performed to assess the biological effect of rFeIFN-omega.Changes in blood cell count, increases in serum aspartate-amino-transferase activity, serum bilirubin concentration, serum creatinine and serum electrolyte concentrations, weight loss, anorexia, increased body temperature, and reduced general condition were observed but were mostly minor (grade 1 and 2) and self limiting. Eosinophilia (P = .025), neutropenia (P = .021), and weight loss (P < .001) were statistically correlated with rFeIFN-omega-treatment (analysis of parameters before treatment and after 3 injections of rFeIFN-omega). Flow cytometry of 5 unrelated feline fibrosarcoma cell lines showed increased expression of major histocompatibility complex (MHC) class I molecules (P = .026) in response to in vitro incubation with rFeIFN-omega, whereas expression of MHC class II molecules was not affected significantly.RFeIFN-omega for the treatment of feline fibrosarcoma is safe, well tolerated, and can be easily performed in practice. To assess the efficacy of the treatment, it should be tested in a placebo-controlled trial." @default.
• W2001503306 created "2016-06-24" @default.
• W2001503306 creator A5002924973 @default.
• W2001503306 creator A5004936675 @default.
• W2001503306 creator A5008211267 @default.
• W2001503306 creator A5011328404 @default.
• W2001503306 creator A5011380607 @default.
• W2001503306 creator A5020349888 @default.
• W2001503306 creator A5021417789 @default.
• W2001503306 creator A5039310557 @default.
• W2001503306 creator A5053687393 @default.
• W2001503306 date "2007-01-01" @default.
• W2001503306 modified "2023-10-14" @default.
• W2001503306 title "Adjuvant Immunotherapy of Feline Fibrosarcoma with Recombinant Feline Interferon-ω" @default.
• W2001503306 cites W129844587 @default.
• W2001503306 cites W1619940129 @default.
• W2001503306 cites W1968303285 @default.
• W2001503306 cites W1972098617 @default.
• W2001503306 cites W1980041786 @default.
• W2001503306 cites W1981649984 @default.
• W2001503306 cites W1986616957 @default.
• W2001503306 cites W1990213618 @default.
• W2001503306 cites W1998576798 @default.
• W2001503306 cites W1998650748 @default.
• W2001503306 cites W1999380555 @default.
• W2001503306 cites W2003090436 @default.
• W2001503306 cites W2012435744 @default.
• W2001503306 cites W2013010859 @default.
• W2001503306 cites W2015441810 @default.
• W2001503306 cites W2016749262 @default.
• W2001503306 cites W2017274161 @default.
• W2001503306 cites W2018926341 @default.
• W2001503306 cites W2020920166 @default.
• W2001503306 cites W2022146972 @default.
• W2001503306 cites W2029989579 @default.
• W2001503306 cites W2032276655 @default.
• W2001503306 cites W2041557765 @default.
• W2001503306 cites W2043516182 @default.
• W2001503306 cites W2045246330 @default.
• W2001503306 cites W2056734770 @default.
• W2001503306 cites W2058232574 @default.
• W2001503306 cites W2060555060 @default.
• W2001503306 cites W2073765371 @default.
• W2001503306 cites W2074779600 @default.
• W2001503306 cites W2079417363 @default.
• W2001503306 cites W2088704237 @default.
• W2001503306 cites W2094631594 @default.
• W2001503306 cites W2103565638 @default.
• W2001503306 cites W2146262463 @default.
• W2001503306 cites W2156057520 @default.
• W2001503306 cites W2171127432 @default.
• W2001503306 cites W2263807315 @default.
• W2001503306 cites W2319052763 @default.
• W2001503306 cites W2415502126 @default.
• W2001503306 cites W2471129642 @default.
• W2001503306 cites W4235987765 @default.
• W2001503306 doi "https://doi.org/10.1892/06-201.1" @default.
• W2001503306 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7197455" @default.
• W2001503306 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18196745" @default.
• W2001503306 hasPublicationYear "2007" @default.
• W2001503306 type Work @default.
• W2001503306 sameAs 2001503306 @default.
• W2001503306 citedByCount "9" @default.
• W2001503306 countsByYear W20015033062013 @default.
• W2001503306 countsByYear W20015033062014 @default.
• W2001503306 countsByYear W20015033062017 @default.
• W2001503306 countsByYear W20015033062019 @default.
• W2001503306 countsByYear W20015033062020 @default.
• W2001503306 countsByYear W20015033062023 @default.
• W2001503306 crossrefType "journal-article" @default.
• W2001503306 hasAuthorship W2001503306A5002924973 @default.
• W2001503306 hasAuthorship W2001503306A5004936675 @default.
• W2001503306 hasAuthorship W2001503306A5008211267 @default.
• W2001503306 hasAuthorship W2001503306A5011328404 @default.
• W2001503306 hasAuthorship W2001503306A5011380607 @default.
• W2001503306 hasAuthorship W2001503306A5020349888 @default.
• W2001503306 hasAuthorship W2001503306A5021417789 @default.
• W2001503306 hasAuthorship W2001503306A5039310557 @default.
• W2001503306 hasAuthorship W2001503306A5053687393 @default.
• W2001503306 hasBestOaLocation W20015033062 @default.
• W2001503306 hasConcept C126322002 @default.
• W2001503306 hasConcept C142724271 @default.
• W2001503306 hasConcept C203014093 @default.
• W2001503306 hasConcept C2776495794 @default.
• W2001503306 hasConcept C2776694085 @default.
• W2001503306 hasConcept C2777063308 @default.
• W2001503306 hasConcept C2779904517 @default.
• W2001503306 hasConcept C71924100 @default.
• W2001503306 hasConcept C90924648 @default.
• W2001503306 hasConceptScore W2001503306C126322002 @default.
• W2001503306 hasConceptScore W2001503306C142724271 @default.
• W2001503306 hasConceptScore W2001503306C203014093 @default.
• W2001503306 hasConceptScore W2001503306C2776495794 @default.
• W2001503306 hasConceptScore W2001503306C2776694085 @default.
• W2001503306 hasConceptScore W2001503306C2777063308 @default.
• W2001503306 hasConceptScore W2001503306C2779904517 @default.
• W2001503306 hasConceptScore W2001503306C71924100 @default.
• W2001503306 hasConceptScore W2001503306C90924648 @default.

• next